The HAART side of resource allocation.
作者信息
Sendi Pedram, Gafni Amiram
机构信息
Institute for Clinical Epidemiology and the Division of Infectious Diseases, Basel University Hospital, Basel, Switzerland.
出版信息
CMAJ. 2003 Jul 22;169(2):120-1.
Abstract
摘要
相似文献
1
The HAART side of resource allocation.资源分配中的高效抗逆转录病毒治疗方面
CMAJ. 2003 Jul 22;169(2):120-1.
2
The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.1995 - 2001年期间，艾滋病病毒/艾滋病患者医疗护理直接成本的变化情况。
CMAJ. 2003 Jul 22;169(2):106-10.
3
Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART.在引入高效抗逆转录病毒治疗（HAART）后，德国一个队列中治疗HIV感染的直接费用。
Eur J Med Res. 2002 Nov 25;7(11):463-71.
4
Highly active antiretroviral therapy (HAART)--plus: next steps to enhance HAART in resource-limited areas?高效抗逆转录病毒疗法（HAART）——此外：在资源有限地区加强HAART的后续步骤？
Clin Infect Dis. 2007 Dec 1;45(11):1499-501. doi: 10.1086/522992. Epub 2007 Oct 22.
5
The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life.意大利北部地区艾滋病毒/艾滋病的社会负担：成本与生活质量分析
AIDS Care. 2008 Apr;20(4):449-55. doi: 10.1080/09540120701867107.
6
Providing antiretroviral therapy for HIV infection.为艾滋病毒感染提供抗逆转录病毒疗法。
N Engl J Med. 2001 Mar 15;344(11):844-6. doi: 10.1056/NEJM200103153441112.
7
Do reduced inpatient costs associated with highly active antiretroviral therapy (HAART) balance the overall cost for HIV treatment?高效抗逆转录病毒疗法（HAART）是否降低了与艾滋病治疗相关的住院费用，从而平衡了整体治疗成本？
Appl Health Econ Health Policy. 2010;8(2):75-88. doi: 10.2165/11531890-000000000-00000.
8
Balancing effectiveness and access to HIV treatment in the developing world.在发展中世界平衡艾滋病治疗的有效性与可及性。
AIDS. 2007 Jan 30;21(3):361-3. doi: 10.1097/QAD.0b013e328012c560.
9
Costing universal access of highly active antiretroviral therapy in Benin.贝宁普及高效抗逆转录病毒疗法的成本核算
AIDS Care. 2008 May;20(5):582-7. doi: 10.1080/09540120701868303.
10
Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.1997年至2006年某地区人群中感染艾滋病毒患者的医疗费用。
HIV Med. 2008 Oct;9(9):721-30. doi: 10.1111/j.1468-1293.2008.00613.x. Epub 2008 Jul 17.
引用本文的文献
1
The increasingly complex fourth hurdle for pharmaceuticals.制药行业日益复杂的第四道难关。
Pharmacoeconomics. 2007;25(9):727-34. doi: 10.2165/00019053-200725090-00002.
本文引用的文献
1
Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty.重新审视确定性和不确定性条件下成本效益分析的决策规则。
Soc Sci Med. 2003 Sep;57(6):969-74. doi: 10.1016/s0277-9536(02)00477-x.
2
The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.1995 - 2001年期间，艾滋病病毒/艾滋病患者医疗护理直接成本的变化情况。
CMAJ. 2003 Jul 22;169(2):106-10.
3
4
Opportunity costs and uncertainty in the economic evaluation of health care interventions.医疗保健干预措施经济评估中的机会成本与不确定性
Health Econ. 2002 Jan;11(1):23-31. doi: 10.1002/hec.641.
5
Analysis of costs and cost-effectiveness in multinational trials.跨国试验中的成本与成本效益分析。
Health Policy. 2001 Nov;58(2):175-86. doi: 10.1016/s0168-8510(01)00142-7.
6
Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection.高效抗逆转录病毒疗法：HIV感染管理中的药物经济学问题。
Pharmacoeconomics. 2001;19(7):709-13. doi: 10.2165/00019053-200119070-00001.
7
The cost effectiveness of combination antiretroviral therapy for HIV disease.抗逆转录病毒联合疗法治疗HIV疾病的成本效益
N Engl J Med. 2001 Mar 15;344(11):824-31. doi: 10.1056/NEJM200103153441108.
8
Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy.高效抗逆转录病毒治疗时代艾滋病病毒感染患者的护理费用。
N Engl J Med. 2001 Mar 15;344(11):817-23. doi: 10.1056/NEJM200103153441107.
9
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.依非韦伦加齐多夫定和拉米夫定、依非韦伦加茚地那韦以及茚地那韦加齐多夫定和拉米夫定用于治疗成人HIV-1感染。006研究团队。
N Engl J Med. 1999 Dec 16;341(25):1865-73. doi: 10.1056/NEJM199912163412501.
10
Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study.高效抗逆转录病毒疗法对HIV感染患者的成本效益。瑞士HIV队列研究。
AIDS. 1999 Jun 18;13(9):1115-22. doi: 10.1097/00002030-199906180-00016.
Zotero 插件